When Alex Smith went down with one of the most frightening injuries in National Football League (NFL) history — an injury so ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Down by as many as 33, the Wizards cut the deficit to four in the fourth quarter before the Knicks pull away to hand Washington its fourth straight loss. Alex Sarr continues his strong play with ...

Motorsport journalist Rob Peeters breaks down Red Bull's plans for Liam Lawson, examines IndyCar's issues in Thermal and recaps the NASCAR weekend in Homestead. Allison Seymour brings you ...

Gilead said two ex­per­i­men­tal once-a-year ver­sions of its HIV pre­ven­tion shot lenaca­pavir passed muster in an ear­ly-stage study with a small group of healthy par­tic­i­pants … ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

The U.S. Department of Education has warned several universities in Washington state that they could lose out on federal funding due to possible violations of Title VI of the Civil Rights Act ...

Gilead Sciences (GILD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the ...